Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

Esophageal Cancer Clinical Trial

Official title:

A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01393483
• Other study ID #: 11-037
• Status: Active, not recruiting
• Start date: March 2011
• Est. completion date: September 2024

Study information

• Verified date: October 2022
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to find out whether a protein, called mesothelin, found in the blood and tissue can be used as "marker" for esophageal cancer. Doctors at Memorial Sloan-Kettering Cancer Center would like to compare levels of this protein in patients with abnormal cells or tissue of the esophageal to the levels of this protein in patients being treated for cancer for the esophagus.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 371
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with T1 adenocarcinoma or suspected adenocarcinoma who are scheduled for a biopsy and mucosal resection (Group 1)

• Patients with a T1-2N0 adenocarcinoma or suspected adenocarcinoma who are scheduled to undergo and esophagectomy (Group 2)

• Patients with T2N1 and T3N0-1 adenocarcinoma or suspected adenocarcinoma who are scheduled to undergo endoscopy and biopsy and/or endoscopic ultrasound and biopsy prior to pre-operative chemo-radiotherapy and have baseline and surgical tissue available for staining (Group 3)

Exclusion Criteria:

• Patients <18 years of age

• Patients unfit medically for endoscopy surveillance and therapy

• Patients unfit medically for esophagectomy

• Patients with stage IV esophageal adenocarcinoma

• Patients previously treated with chemo-radiotherapy for their esophageal cancer

• Patients with squamous cell carcinoma of the esophagus

• Patients who have a history of cancer within 3 years or have a concurrent cancer.

Related Conditions & MeSH terms

• Adenocarcinoma
• Esophageal Cancer

Intervention

Other:
• serum and tissue mesothelin
Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period. Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs.
• serum and tissue mesothelin
Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
• serum and tissue mesothelin
Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate prospectively what proportion of esophageal adenocarcinomas express tissue.	The investigators will examine the range and variability in the percentage on cells stained (for TM) and in the absolute value (for SM). TM expression is commonly analyzed in a binary fashion, with 25% of cells stained indicating positive expression (per standard pathological guidelines for tissue staining)	2 years
Primary	To evaluate prospectively if serum mesothelin levels correlate to clinical stage in esophageal adenocarcinomas	The investigators will explore the optimal cut point that defines positive expression. Serum mesothelin (SM) will be measured and analyzed whenever possible on a continuous scale.	2 years
Primary	To evaluate prospectively if clinical response to induction chemotherapy	First, the investigators will use two-sample t-tests to determine whether the initial responders to induction chemotherapy (defined as >30% decrease in SUV at the repeat PET) differ from non-responders in their 1) baseline (pre-induction) SM value, and 2) percent change in SM value between pre-induction and mid-induction (after 2 cycles) evaluations.	2 years
Primary	To evaluate prospectively if clinical response to concurrent chemo-radiation correlates to serum mesothelin levels	The investigators will take the following steps in order to assess the ability of SM at the time of resection with curative intent to predict disease recurrence: 1) we will examine the association between SM and the risk of recurrence by fitting a Cox proportional hazards model (after appropriate transformation of the SM value and checking of the PH assumption	2 years
Secondary	To evaluate whether expression of tissue mesothelin is a predictor of recurrence	The investigators will Wilcoxon test to investigate the association between serum mesothelin and tissue mesothelin at each time point where both markers are evaluated, and will further attempt to obtain an aggregate measure of this correlation using clustered Wilcoxon test, which accounts for multiple measurements per patient (14).	2 years
Secondary	To evaluate whether expression of tissue mesothelin is a predictor of poor response to chemotherapy	Mesothelin positive tumors (MES+) will be defined as strong staining in > 25% of the tumor cells and mesothelin negative tumors (MES-) are defined as <= 25% cytoplasmic staining. Serum mesothelin will be collected and analyzed, whenever possible, on a continuous scale.	2 years
Secondary	To evaluate for the presence of any confounders in the putative association between serum mesothelin expression and the risk of recurrence		2 years
Secondary	To evaluate the correlation between serum mesothelin levels and tissue expression		2 years

External Links

•   Memorial Sloan Kettering Cancer Center